Connection domain mutations in HIV-1 reverse transcriptase do not impact etravirine susceptibility and virologic responses to etravirine-containing regimens.
PMID: 21464253
2011
Antimicrobial agents and chemotherapy
Abstract: N348I or T369I was associated with reduced etravirine susceptibility when present with K101P or K103R/V179D.
Drug resistance mutations during structured interruptions of HAART in two HIV-1-infected children.
Abstract: Although the mutation K103R associated with non-nucleoside reverse transcriptase inhibitor resistance was found in two viral rebounds of one patient, the analysis indicated the absence of resistance to RT inhibitors.
New trends of primary drug resistance among HIV type 1-infected men who have sex with men in Liaoning Province, China.
PMID: 21417755
2011
AIDS research and human retroviruses
Abstract: L10I (4.5%), V118I/IV (17.4%), and K103R/KR (10.0%) were commonly observed mutations, but do not confer any drug resistance to PIs, NRTIs, and NNRTIs.
Failure of initial therapy with two nucleosides and efavirenz is not associated with early emergence of mutations in the C-terminus of HIV-1 reverse transcriptase.
PMID: 21350368
2011
Journal of acquired immune deficiency syndromes (1999)
Result: Pre-therapy mutations associated with virologic failure, unadjusted for multiple comparisons, were E6D (p=0.023), K103R (p=0.046) and Q174K (p=0.015) in the polymerase domain and Q334H in the connection domain (p=0.045) [Table 2].
Prevalence and clinical significance of HIV drug resistance mutations by ultra-deep sequencing in antiretroviral-naive subjects in the CASTLE study.
Low-abundance HIV species and their impact on mutational profiles in patients with virological failure on once-daily abacavir/lamivudine/zidovudine and tenofovir.
PMID: 20008905
2010
The Journal of antimicrobial chemotherapy
Result: K103R, Y181H and G190E) from archived drug-resistant virus were also detected in some baseline samples by CG.
Table: K103R
Parallel synthesis, molecular modelling and further structure-activity relationship studies of new acylthiocarbamates as potent non-nucleoside HIV-1 reverse transcriptase inhibitors.
PMID: 19058881
2009
European journal of medicinal chemistry
Abstract: Several ATCs were active at micromolar concentrations against HIV-1 strains carrying the RT Y181C mutation and one of them was also moderately active against the K103R variant.
Novel modifications in the series of O-(2-phthalimidoethyl)-N-substituted thiocarbamates and their ring-opened congeners as non-nucleoside HIV-1 reverse transcriptase inhibitors.
PMID: 18954921
2009
European journal of medicinal chemistry
Abstract: Compound 56 combined the highest activity so far identified against Y181C (EC(50)=1.3 microM) with good potency against the K103R mutant (EC(50)=4.8 microM).
Application of an allele-specific PCR to clinical HIV genotyping samples detects additional K103N mutations in both therapy naive and experienced patients.
Abstract: When applied to samples from patients presenting for genotyping, the ASP detects K103N, not K103 nor K103R, but cross-reacts with K103S.
In utero HIV infection is associated with an increased risk of nevirapine resistance in ugandan infants who were exposed to perinatal single dose nevirapine.
PMID: 19552593
2009
AIDS research and human retroviruses
Introduction: Eight infants had mutations detected by ViroSeq [Y181C (n = 4), K103N (n = 1), V106M (n = 1), Y188C (n = 1), and V179D+K103R (n = 1)], and four infants had resistance detected by LigAmp only (all with Y181C, at 1.2%, 1.4%, 3.5%, and 7.8%; one infant also had G190A at 1.9%).
HIV mutation literature information.
PMID: 
2011
Antimicrobial agents and chemotherapy
Browser Board
Co-occurred Entities
Filtrator
ViMRT